Cover Image
市場調查報告書

日本的OCT導管市場

Japan Market Report for Optical Coherence Tomography Catheters 2018 - MedCore

出版商 iData Research Inc. 商品編碼 616045
出版日期 內容資訊 英文 675 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
日本的OCT導管市場 Japan Market Report for Optical Coherence Tomography Catheters 2018 - MedCore
出版日期: 2017年10月01日 內容資訊: 英文 675 Pages
簡介

本報告提供日本的OCT (光學同調斷層掃瞄) 導管市場相關調查分析,提供疾病概要,產品的評估,市場分析相關的系統性資訊。

摘要整理

日本的心血管介入設備市場概要

競爭分析

市場趨勢

市場發展

對象市場

治療數量

版本履歷

第1章 調查手法

第2章 疾病概要

  • 基本結構
  • 疾病的治療和診斷
  • 患者的人口動態

第3章 產品的評估

  • 產品系列
  • 法規問題和回收
  • 臨床實驗

第4章 OCT導管市場

  • 簡介
  • 市場分析與預測
  • 促進因素及阻礙因素
    • 推動市場要素
    • 市場阻礙因素
  • 競爭市場佔有率分析

簡稱

附錄

目錄
Product Code: iDATA_JPIC18_MC_OCT

Optical coherence tomography (OCT) is an imaging modality that can create extremely high resolution three-dimensional images of biological tissues and has proven to be very effective for interventional purposes. While OCT has been used for a number of years in other medical fields, such as in ophthalmology, it has only recently been applied to cardiology. In 2017, only a few OCT systems were approved by the FDA for use in cardiology. However, OCT systems were being used for producing high resolution images of arteries in a clinical setting since 2006 in Japan and Europe.

General Report Contents:

  • Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
  • Market Drivers & Limiters for each chapter segment
  • Competitive Analysis for each chapter segment
  • Section on recent mergers & acquisitions

OCT delivers high resolution because it utilizes light, rather than sound or radio frequencies. In coronary applications, OCT involves directing an optical beam from a catheter extended into the artery of interest. This light penetrates with a depth of 1 mm to 2 mm into the tissue and a small portion of the light that reflects from the sub-surface features is collected. The majority of this collected light is not reflected, but scattered in a way that causes an effect similar to glare. However, the OCT technique can filter out this reflected light, allowing it to produce an image based only on the small proportion of the collected light that is reflected by the tissues.

Because OCT can only image tissues at a depth of a few millimeters, it must be performed endovascularly in cardiology applications. As a result, OCT is most often compared to another imaging technology, intravascular ultrasound (IVUS). Compared to IVUS, OCT produces much higher resolution images, but it cannot produce as broad an image of the cardiovascular system. The main drawback of first generation OCT systems compared to IVUS is the fact that blood flow through the artery must be stopped (for a short time) with a specialized catheter prior to OCT imaging. This is due to the fact that blood can attenuate the OCT optical beam. While this drawback existed in the majority of first generation OCT systems used in Europe and Japan, second generation systems operating on the concept of optical frequency domain imaging (OFDI) are expected to mitigate this problem. OFDI is capable of acquiring images at much higher frame rates than standard OCT, allowing for the imaging of coronary arteries following a brief flush of the artery with saline. Please note that OFDI is sometimes referred to as Fourier domain optical coherence tomography (FD-OCT).

Table of Contents

TABLE OF CONTENTS I

LIST OF FIGURES XXII

LIST OF CHARTS XXX

EXECUTIVE SUMMARY 1

JAPAN INTERVENTIONAL CARDIOLOGY MARKET OVERVIEW 1

COMPETITIVE ANALYSIS 4

MARKET TRENDS 7

MARKET DEVELOPMENTS 9

MARKETS INCLUDED 10

PROCEDURES INCLUDED 11

VERSION HISTORY 11

RESEARCH METHODOLOGY 12

    • Step 1: Project Initiation & Team Selection 12
    • Step 2: Prepare Data Systems and Perform Secondary Research 15
    • Step 3: Preparation for Interviews & Questionnaire Design 17
    • Step 4: Performing Primary Research 18
    • Step 5: Research Analysis: Establishing Baseline Estimates 20
    • Step 6: Market Forecasts and Analysis 21
    • Step 7: Identify Strategic Opportunities 23
    • Step 8: Final Review and Market Release 24
    • Step 9: Customer Feedback and Market Monitoring 25

DISEASE OVERVIEW 26

  • 2.1 BASIC ANATOMY 26
  • 2.2 DISEASE TREATMENTS AND DIAGNOSTICS 28
    • 2.2.1 General Diagnostics 28
    • 2.2.2 Coronary Artery Disease (CAD) 28
    • 2.2.3 Myocardial Infarction (MI) 29
    • 2.2.4 Angina Pectoris 30
  • 2.3 PATIENT DEMOGRAPHICS 31
    • 2.3.1 General Statistics 31

PRODUCT ASSESSMENT 33

  • 3.1 PRODUCT PORTFOLIOS 33
    • 3.1.1 Coronary Catheters Market 33
      • 3.1.1.1 Diagnostic Coronary Catheter 33
      • 3.1.1.2 Interventional Coronary Catheters 34
      • 3.1.1.3 Intravascular Ultrasound (IVUS) Catheter 34
      • 3.1.1.4 Optical Coherence Tomography (OCT) Catheter 35
  • 3.2 REGULATORY ISSUES AND RECALLS 41
    • 3.2.1 Boston Scientific 41
      • 3.2.1.1 Coronary Stent 41
      • 3.2.1.2 PTCA Balloon Catheter 41
      • 3.2.1.3 Interventional Coronary Catheters and Guidewires 42
      • 3.2.1.4 Coronary Embolic Protection Device 43
    • 3.2.2 Cardinal Health 43
      • 3.2.2.1 Coronary Vascular Closure Device 43
    • 3.2.3 Cook Medical 44
      • 3.2.3.1 Coronary Stent 44
      • 3.2.3.2 Interventional Coronary Catheters and Guidewires 44
    • 3.2.4 Cordis (Cardinal Health) 45
      • 3.2.4.1 PTCA Balloon Catheter/Dilation Catheters 45
      • 3.2.4.2 Interventional Coronary Catheters and Guidewires 46
    • 3.2.5 Medtronic 47
      • 3.2.5.1 Coronary Stent 47
      • 3.2.5.2 PTCA Balloon and Dilation Catheters 47
      • 3.2.5.3 Interventional Coronary Catheters and Guidewires 48
    • 3.2.6 Merit Medical Systems 51
      • 3.2.6.1 Interventional Coronary Catheters and Guidewires 51
      • 3.2.6.2 Coronary Introducer Sheath 53
    • 3.2.7 Spectranetics 54
      • 3.2.7.1 Coronary Atherectomy Device 54
    • 3.2.8 St. Jude Medical (Abbott Laboratories) 55
      • 3.2.8.1 Coronary Vascular Closure Device 55
      • 3.2.8.2 Interventional Coronary Catheters and Guidewires 55
    • 3.2.9 Vascular Solutions (Teleflex) 56
      • 3.2.9.1 Interventional Coronary Catheters and Guidewires 56
    • 3.2.10 Volcano Therapeutics (Philips Volcano) 57
      • 3.2.10.1 Interventional Coronary Catheters and Guidewires 57
      • 3.2.10.2 Intravascular Ultrasound (IVUS) Catheter 57
    • 3.2.11 Other Companies 58
      • 3.2.11.1 Coronary Stent and other Vascular Stents 58
      • 3.2.11.2 PTCA balloon catheter 58
      • 3.2.11.3 Interventional Coronary Catheters and Guidewires 59
      • 3.2.11.4 Coronary Atherectomy Device 61
      • 3.2.11.5 Coronary Introducer Sheath 62
      • 3.2.11.6 Intravascular Ultrasound (IVUS) Catheter 62
  • 3.3 CLINICAL TRIALS 63
    • 3.3.1 Abbott Laboratories 63
      • 3.3.1.1 Coronary Stent 63
    • 3.3.2 Asahi Intecc 72
      • 3.3.2.1 Interventional Coronary Catheters and Guidewires 72
    • 3.3.3 B. Braun 73
      • 3.3.3.1 Coronary Stent 73
      • 3.3.3.2 PTCA balloon catheter 74
    • 3.3.4 Biosensors 78
      • 3.3.4.1 Coronary Stent 78
    • 3.3.5 Biotronik 80
      • 3.3.5.1 Coronary Stent 80
      • 3.3.5.2 PTCA balloon catheter 83
    • 3.3.6 Boston Scientific 84
      • 3.3.6.1 Coronary Stent 84
      • 3.3.6.3 PTCA balloon catheter 87
      • 3.3.6.4 Coronary Embolic Protection Device 87
    • 3.3.7 Medtronic 88
      • 3.3.7.1 Coronary Stent 88
      • 3.3.7.2 Interventional Coronary Catheters and Guidewires 91
      • 3.3.7.3 Coronary Embolic Protection Device 92
    • 3.3.8 St. Jude Medical (Abbott Laboratories) 93
      • 3.3.8.1 Interventional Coronary Catheters and Guidewires 93
      • 3.3.8.2 Intravascular Ultrasound (IVUS) Catheter 93
      • 3.3.8.3 Optical Coherence Tomography Catheter 94
      • 3.3.8.4 Fractional Flow Reverse (FFR) Catheter 94
    • 3.3.9 Terumo Interventional Systems (TIS) 95
      • 3.3.9.1 Interventional Coronary Catheters and Guidewires 95
      • 3.3.9.2 Coronary Embolic Protection Device 95
    • 3.3.10 Other Companies 96
      • 3.3.10.1 Coronary Stent 96
      • 3.3.10.2 PTCA balloon catheter 108
      • 3.3.10.3 Interventional Coronary Catheters and Guidewires 109
      • 3.3.10.4 Coronary Embolic Protection Device 112
      • 3.3.10.5 Coronary Chronic Total Occlusion Crosser CTO 113
      • 3.3.10.7 Fractional Flow Reserve (FFR) Guidewire 114
      • 3.3.10.8 Optical Coherence Tomography (OCT) Guidewire 114

OPTICAL COHERENCE TOMOGRAPHY CATHETER MARKET 116

  • 4.1 INTRODUCTION 116
  • 4.2 MARKET ANALYSIS AND FORECAST 118
  • 4.3 DRIVERS AND LIMITERS 120
    • 4.3.1 Market Drivers 120
    • 4.3.2 Market Limiters 120
  • 4.4 COMPETITIVE MARKET SHARE ANALYSIS 122

ABBREVIATIONS 124

APPENDIX: COMPANY PRESS RELEASES 126

LIST OF CHARTS

  • Chart 1 1: Interventional Cardiology Market by Segment, Japan, 2014 - 2024 3
  • Chart 1 2: Interventional Cardiology Market Overview, Japan, 2017 & 2024 3
  • Chart 4 1: Optical Coherence Tomography Catheter Market, Japan, 2014 - 2024 119
  • Chart 4 2: Leading Competitors, Optical Coherence Tomography Catheter Market, Japan, 2017 123

LIST OF FIGURES

  • Figure 1 1: Interventional Cardiology Market Share Ranking by Segment, Japan, 2017 (1 of 2) 4
  • Figure 1 2: Interventional Cardiology Market Share Ranking by Segment, Japan, 2017 (2 of 2) 5
  • Figure 1 3: Companies Researched in this Report, Japan, 2017 6
  • Figure 1 4: Factors Impacting the Interventional Cardiology Market by Segment, Japan (1 of 2) 7
  • Figure 1 5: Factors Impacting the Interventional Cardiology Market by Segment, Japan (2 of 2) 8
  • Figure 1 6: Recent Events in the Interventional Cardiology Market, Japan, 2014 - 2017 9
  • Figure 1 7: Interventional Cardiology Markets Covered, Japan, 2017 10
  • Figure 1 8: Interventional Cardiology Procedures Covered, Japan, 2017 11
  • Figure 1 9: Version History 11
  • Figure 3 1: Coronary Catheters Products by Company (1 of 3) 37
  • Figure 3 2: Coronary Catheters Products by Company (2 of 3) 38
  • Figure 3 3: Coronary Catheters Products by Company (3 of 3) 39
  • Figure 3 4: Imaging Catheter Products by Company 40
  • Figure 3 5: Class 1 Device Recall Boston Scientific Fetch 2 Aspiration Catheter 41
  • Figure 3 6: Class 2 Device Recall Boston Scientific, Small Peripheral Cutting BalloonTM 41
  • Figure 3 7: Class 2 Device Recall Boston Scientific, FlextomeTM Cutting BalloonTM 41
  • Figure 3 8: Class 2 Device Recall Boston Scientific ACUITY Pro Coronary Sinus Guide Catheter 42
  • Figure 3 9: Class 1 Device Recall Boston Scientific Fetch 2 Aspiration Catheter 42
  • Figure 3 10: Class 2 Device Recall Boston Scientific, FlextomeTM Cutting BalloonTM 42
  • Figure 3 11: Class 1 Device Recall RotaWire Elite and sireClip Torquer, Guidewire and Guidewire Manipulation Device, Floppy 43
  • Figure 3 12: Class 2 Device Recall MynxGrip Vascular Closure Device 43
  • Figure 3 13: Class 2 Device Recall Zilver 518RX Vascular Stent 44
  • Figure 3 14: Class 2 Device Recall Zilver 518 Vascular Self Expanding Stent 44
  • Figure 3 15: Class 2 Device Recall White Lumax Guiding Coaxial Catheter 44
  • Figure 3 16: Class 2 Device Recall Cordis POWERFLEX PRO PTA Dilatation Catheter 45
  • Figure 3 17: Class 2 Device Recall EMPIRA ? NC RX PTCA Dilatation Catheter 45
  • Figure 3 18: Class 2 Device Recall Cordis EMPIRA RX PTCA Dilatation Catheter 45
  • Figure 3 19: Class 2 Device Recall Cordis ADROIT 6F Guiding Catheter 46
  • Figure 3 20: Class 2 Device Recall Resolute Integrity Zotarolimuseluting Coronary Stent 47
  • Figure 3 21: Class 2 Device Recall PowerCross .018 OTW PTA Dilation Catheter 47
  • Figure 3 22: Class 2 Device Recall Ev3, Inc. (Medtronic) 47
  • Figure 3 23: Class 2 Device Recall NC Sprinter; Rapid Exchange Balloon Dilatation Catheter 48
  • Figure 3 24: Class 2 Device Recall Medtronic Launcher Coronary Guide Catheter 48
  • Figure 3 25: Class 2 Device Recall Launcher Coronary Guiding Catheter 48
  • Figure 3 26: Class 1 Device Recall ZINGER Steerable Guidewire 48
  • Figure 3 27: Class 1 Device Recall Cougar Nitinol Workhorse Guidewire 49
  • Figure 3 28: Class 1 Device Recall COUGAR Steerable Guidewire 49
  • Figure 3 29: Class 1 Device Recall THUNDER Steerable Guidewire 49
  • Figure 3 30: Class 1 Device Recall ProVia CROSSING GUIDEWIRE 49
  • Figure 3 31: Class 1 Device Recall ATTAIN HYBRID Guide Wire 50
  • Figure 3 32: Class 2 Device Recall Medtronic Zuma Guide Catheter 50
  • Figure 3 33: Class 2 Device Recall Merit Maestro Microcatheter 51
  • Figure 3 34: Class 2 Device Recall Merit Laureate Hydrophilic Guide Wire 51
  • Figure 3 35: Class 2 Device Recall Maestro Microcatheter, Merit Medical System 51
  • Figure 3 36: Class 2 Device Recall Performa Cardiac Multipack Catheter 52
  • Figure 3 37: Class 2 Device Recall Hydrophylic guidewire 52
  • Figure 3 38: Class 2 Device Recall PreludeEASE 53
  • Figure 3 39: Class 2 Device Recall Prelude Pro Sheath Introducter 53
  • Figure 3 40: Class 2 Device Recall Turbo Elite Atherectomy Catheter 54
  • Figure 3 41: Class 2 Device Recall ELCA Coronary Atherectomy Catheter 54
  • Figure 3 42: Class 2 Device Recall Vascular closure device 55
  • Figure 3 43: Class 3 Device Recall FastCath" Transseptal Guiding Introducer 55
  • Figure 3 44: Class 1 Device Recall TwinPass Dual Access Catheter 56
  • Figure 3 45: Class 2 Device Recall Percutaneous Catheter 56
  • Figure 3 46: Class 2 Device Recall Prestige Plus Wire 57
  • Figure 3 47: Class 2 Device Recall Volcano s5, s5i, CORE and CORE Mobile systems 57
  • Figure 3 48: Class 2 Device Recall Intravascular Ultrasound System 57
  • Figure 3 49: Class 2 Device Recall FLAIR Endovascular Stent Graft, Bard Peripheral Vascular 58
  • Figure 3 50: Class 1 Device Recall LifeStent Solo Vascular Stent, Bard Peripheral Vascular 58
  • Figure 3 51: Class 2 Device Recall PTA Balloon Dilatation Catheters 58
  • Figure 3 52: Class 2 Device Recall VIA 27 Microcatheters, Sequent Medical Inc. 59
  • Figure 3 53: Class 2 Device Recall Coronary Artery Perfusion Cannula with Balloon, Sorin Group USA, Inc. 59
  • Figure 3 54: Class 2 Device Recall Aortic Arch Cannula, Sorin Group USA, Inc. 59
  • Figure 3 55: Class 2 Device Recall Mallinckrodt Launcher Guiding Catheter, Stryker Sustainability Solutions 59
  • Figure 3 56: Class 2 Device Recall Distal Access Catheter (DAC), Concentric Medical Inc 60
  • Figure 3 57: Class 2 Device Recall Distal Access Catheter 60
  • Figure 3 58: Class 2 Device Recall Proplege Coronary Sinus Catheter, Edwards Lifesciences, LLC 60
  • Figure 3 59: Class 2 Device Recall Turbo Elite, ELCA Atherectomy Catheter, Spectranetics Corporation 61
  • Figure 3 60: Class 1 Device Recall Diamondback 360 Coronary Orbital Artherctomy System, Cardiovascular Systems, Inc. 61
  • Figure 3 61: Class 3 Device Recall Diamondback 360 Coronary Orbital Atherectomy System 61
  • Figure 3 62: Class 2 Device Recall VIA 27 Microcatheters, Sequent Medical Inc 62
  • Figure 3 63: Class 1 Device Recall Halo One ThinWalled Guiding Sheath, Bard Peripheral Vascular 62
  • Figure 3 64: Class 2 Device Recall SOUNDSTAR eco Catheter, Biosense Webster, Inc. 62
  • Figure 3 65: XIENCE Xpedition/Alpine in Routine Clinical Practice (IRIS XPEDITION) 63
  • Figure 3 66: Non-inferiority Study Comparing Firehawk Stent With Abbott Xience Family Stent (TARGET-AC) 63
  • Figure 3 67: Trial of MiStent Compared to Xience in Japan (DESSOLVEJ) 64
  • Figure 3 68: Effect and Efficacy of Xpedition™/Alpine™, Everolimus-eluting Stent for Coronary Atherosclerosis (HOST-ALPINE) 64
  • Figure 3 69: XIENCE Xpedition Everolimus-Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE Xpedition SV Japan PMS) 65
  • Figure 3 70: Absorb IV Randomized Controlled Trial 65
  • Figure 3 71: Amsterdam Investigator-initiateD Absorb Strategy All-comers Trial (AIDA) 66
  • Figure 3 72: Xience Versus Synergy in Left Main PCI (IDEAL-LM) 66
  • Figure 3 73: Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent (TALENT) 67
  • Figure 3 74: XIENCE PRIME SV Everolimus Eluting Coronary Stent Post Marketing Surveillance (XIENCE PRIME SV PMS) 67
  • Figure 3 75: XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study (XP China SAS) 68
  • Figure 3 76: A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT) (ABSORB CHINA) 68
  • Figure 3 77: AVJ-301 Clinical Trial: A Clinical Evaluation of AVJ-301 (Absorb™ BVS) in Japanese Population (ABSORB JAPAN) 69
  • Figure 3 78: XIENCE PRIME Japan Post-Marketing Surveillance (PMS) 69
  • Figure 3 79: EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent, Performance, and Technique in Chronic Total Occlusions 70
  • Figure 3 80: Sirolimus-eluting Stent CALYPSO vs Everolimus-eluting Stent XIENCE (PATRIOT) 70
  • Figure 3 81: Stentys Coronary Stent System Clinical Trial in Patients With Acute Myocardial Infarction (APPOSITION V) 71
  • Figure 3 82: Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis (RESTORE) 71
  • Figure 3 83: The Asahi Intecc PTCA Chronic Total Occlusion Study (CTO-PCI) 72
  • Figure 3 84: Optilene® Suture for Coronary Artery Bypass Graft Surgery (OPTICABG) 73
  • Figure 3 85: Treatment of Coronary Artery Disease (CAD) With Bare Metal Stent (BMS) Followed by Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Eluting Stent 73
  • Figure 3 86: Paclitaxel Eluting Balloon Versus Drug Eluting Stent in Native Coronary Artery Stenoses of Diabetic Patients (PEPCAD IV) 74
  • Figure 3 87: Comparison of Agent™ and SeQuent® Please Paclitaxel Coated Balloon Catheters in Coronary In-stent Restenosis (AGENT-ISR) 74
  • Figure 3 88: Paclitaxel-Eluting Balloon Angioplasty and Coroflex™-Stents in the Treatment of Bifurcated Coronary Lesions (PEPCAD V) 75
  • Figure 3 89: The Paclitaxel-Eluting Percutaneous Coronary Angioplasty (PTCA)-Balloon Catheter for the Treatment of Coronary Bifurcations (PEPCAD-BIF) 75
  • Figure 3 90: INDICOR The Paclitaxel-Eluting PTCA-Balloon Catheter in Combination With a Cobalt-Chromium Stent (INDICOR) 76
  • Figure 3 91: A Safety and Efficacy Study of Paclitaxel-eluting Balloon to Paclitaxel-eluting Stent (PEPCAD) 76
  • Figure 3 92: The Paclitaxel-Eluting Percutaneous Transluminal Coronary Angioplasty (PTCA) - Balloon Catheter in Coronary Artery Disease to Treat Chronic Total Occlusions (PEPCAD-CTO) 77
  • Figure 3 93: PEPCAD I. The Paclitaxel-Eluting PTCA-Balloon Catheter to Treat Small Vessel 77
  • Figure 3 94: LEADERS FREE II: BioFreedom™ Pivotal Study 78
  • Figure 3 95: BioFreedom US IDE Feasibility Trial 78
  • Figure 3 96: A Randomized Clinical Evaluation of the BioFreedom™ Stent (Leaders Free) 79
  • Figure 3 97: Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease (ABSORB-LONG) 80
  • Figure 3 98: BIOTRONIK Orsiro Pre-Marketing Registration (BIOFLOW-VI) 80
  • Figure 3 99: Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions 81
  • Figure 3 100: BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III French Satellite 81
  • Figure 3 101: BIOHELIX-I Bare Metal Stent Study (BIOHELIX-I) 82
  • Figure 3 102: BIOFLOW III Asia Registry 82
  • Figure 3 103: BIOFLOW-III Israel Satellite Registry 82
  • Figure 3 104: Study of Vascular Healing With the Combo Stent Versus the Everolimus Eluting Stent in ACS Patients by Means of OCT (REMEDEE-OCT) 83
  • Figure 3 105: Drug Eluting Pantera Lux Catheter Registry 83
  • Figure 3 106: Post-Approval Study of PROMUS Element™ in China (PEChina) 84
  • Figure 3 107: EVOLVE China Clinical Trial (EVOLVE China) 84
  • Figure 3 108: EVOLVE Short DAPT Study 85
  • Figure 3 109: PROMUS Element Plus US Post-Approval Study 85
  • Figure 3 110: The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s) 86
  • Figure 3 111: SYNERGY China: Assess SYNERGY Stent in China 86
  • Figure 3 112: Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter 87
  • Figure 3 113: WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation 87
  • Figure 3 114: Safety and Efficacy of the CRE8 Stent for the Treatment of De Novo Coronary Artery Lesions 88
  • Figure 3 115: RESOLUTE ONYX Post-Approval Study (ONYX PAS) 88
  • Figure 3 116: Medtronic RevElution Trial (RevElution) 89
  • Figure 3 117: The European Bifurcation Club Left Main Study (EBC MAIN) 89
  • Figure 3 118: Medtronic Resolute Onyx 2.0 mm Clinical Study 89
  • Figure 3 119: Medtronic Resolute Onyx Core (2.25 mm - 4.0 mm) Clinical Study 90
  • Figure 3 120: Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use (CHINA RESOLUTE INTEGRITY STUDY) 90
  • Figure 3 121: An Evaluation of the Commercially Available Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System (RI-US) 91
  • Figure 3 122: Randomized Comparison of JUDkins vs tiGEr Catheter in Coronary Angiography Via the Right Radial Artery: the JUDGE Study (JUDGE) 91
  • Figure 3 123: Atrial Fibrillation Detected by Continuous ECG Monitoring (LOOP) 92
  • Figure 3 124: Substrate Targeted Ablation Using the FlexAbility™ Ablation Catheter System for the Reduction of Ventricular Tachycardia (STAR-VT) 93
  • Figure 3 125: ILUMIEN III: OPTIMIZE PCI 93
  • Figure 3 126: ILUMIEN III: OPTIMIZE PCI 94
  • Figure 3 127: Portuguese Study on The Evaluation of FFR Guided Treatment of Coronary Disease (POST-IT) 94
  • Figure 3 128: Randomized Comparison of JUDkins vs tiGEr Catheter in Coronary Angiography Via the Right Radial Artery: the JUDGE Study (JUDGE) 95
  • Figure 3 129: Evaluation of the Roadsaver Stent Used in Conjunction With the Nanoparasol Embolic Protection System for Carotid Artery Stenosis 95
  • Figure 3 130: Firehawk™ Coronary Stent System in the Treatment of Total Coronary Artery Occlusion Lesion(s) 96
  • Figure 3 131: Safety and Efficacy Study of the Amaranth Medical MAGNITUDE Bioresorbable Drug-Eluting Coronary Stent (RENASCENT III) 96
  • Figure 3 132: Trial of MiStent Compared to Xience in Japan (DESSOLVEJ) 97
  • Figure 3 133: MedJ-01 Ridaforolimus Eluting Coronary Stent System Trial (JNIR) (JNIR) 97
  • Figure 3 134: Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation 98
  • Figure 3 135: BIONICS - Pharmacokinetics (PK) Trial (BIONICS) 98
  • Figure 3 136: Safety and Efficacy Study of the Amaranth Medical APTITUDE Bioresorbable Drug-Eluting Coronary Stent (RENASCENT II) 98
  • Figure 3 137: Evaluation of New Specifications (2.25mm) of FirehawkTM in the Treatment of Coronary Heart Disease ( Firehawk_2.25 ) 99
  • Figure 3 138: Evaluation of New Specifications (38mm) of FirehawkTM in the Treatment of Coronary Heart Disease (Firehawk_38) 99
  • Figure 3 139: Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent (MEND II) 100
  • Figure 3 140: Safety and Efficacy Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent (RENASCENT) 100
  • Figure 3 141: Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold (FANTOM II), Reva Medical 100
  • Figure 3 142: Pilot Study of the Fantom Bioresorbable Scaffold (FANTOM I) (FANTOM I), Reva Medical 101
  • Figure 3 143: NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial 101
  • Figure 3 144: A Prospective, Single-arm, Multi-centre, Observational, Real World Registry (Morpheus) 102
  • Figure 3 145: Safety and Efficacy Study of the Svelte Drug-Eluting Coronary Stent Delivery System (DIRECT II) 102
  • Figure 3 146: First-in-man Trial Examining the Safety and Efficacy of BuMA Supreme and Resolute Integrity in Patients With de Novo Coronary Artery Stenosis 103
  • Figure 3 147: eTryton Left Main Registry Tryton Side Branch Stent® Tmt of Denovo CAD in LM and CFX Arteries (eTRYTONLM) 103
  • Figure 3 148: An Evaluation of BioMime™ - Sirolimus Eluting Coronary Stent in a Multi- Centre Study The BioMime™1 Trial (MeriT-II) 104
  • Figure 3 149: An BioMime Vs. Xience Randomised Control Clinical Study (meriT-V) 104
  • Figure 3 150: BIONICS Israel Trial 105
  • Figure 3 151: Elixir Medical Clinical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System 105
  • Figure 3 152: Sapphire II PRO US Clinical Study 106
  • Figure 3 153: Axetis Inert Coronary Stent System First In Man Clinical Investigation (AXETIS FIM) 106
  • Figure 3 154: Shockwave Coronary Rx Lithoplasty® Study (Disrupt CAD I) 106
  • Figure 3 155: Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation 107
  • Figure 3 156: Procedural Advantages of a Novel Drug-Eluting Coronary Stent 107
  • Figure 3 157: Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study 108
  • Figure 3 158: Comparing the Safety and Efficacy of Paclitaxel Controlled Release Balloon Catheter (VasoguardTM) in the Treatment of Small Coronary Vessel Stenosis With a Common Coronary Balloon Catheter (Maverick2) 108
  • Figure 3 159: Drug Eluting Balloon for Prevention of Constrictive Remodeling 109
  • Figure 3 160: Compare the Efficacy and Safety of RESTORE DEB and SeQuent® Please in Chinese Patient With Coronary In-stent Restenosis 109
  • Figure 3 161: Real-time MRI Right Heart Catheterization Using Passive Catheters 110
  • Figure 3 162: A Prospective, Multi-Center, Pivotal Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter in Facilitating Crossing Chronic Total Occlusion (CTO) Coronary Lesions 110
  • Figure 3 163: Safety and Feasibility of Using a Single Transradial Guiding Catheter for Primary PCI (RAPID) 111
  • Figure 3 164: A Prospective, First in Man Study to Evaluate the Safety and Performance of the NovaCross™ Micro-catheter 111
  • Figure 3 165: Performance of the CARDIOGARD Cannula (GECG) 112
  • Figure 3 166: DEFLECT II: A Study to Evaluate the Safety and Performance of the TriGuard™HDH in Patients Undergoing TAVR 112
  • Figure 3 167: Use of the GARDEX™ Embolic Protection Device During Percutaneous Coronary Interventions of Saphenous Vein Graft 113
  • Figure 3 168: Coherex WAVECREST I Left Atrial Appendage Occlusion Study 113
  • Figure 3 169: Trial to Compare FFR Measurement With a Non-Side-Hole Guide Catheter Vs. a Side-Hole Guide Catheter 114
  • Figure 3 170: Prospective Randomized Optical Coherence Tomography Oslo tRial (PROCTOR) 114
  • Figure 3 171: Optical Coherence Tomography Guided Percutaneous Coronary Intervention With Stent Implantation (OCTACS) 115
  • Figure 4 1: Optical Coherence Tomography Catheter Market, Japan, 2014 - 2024 118
  • Figure 4 2: Drivers and Limiters, Optical Coherence Tomography Catheter Market, Japan, 2017 121
  • Figure 4 3: Leading Competitors, Optical Coherence Tomography Catheter Market, Japan, 2017 122
  • Figure 6 1: Press Release Summary 126
Back to Top